Biomarkers for theranostics

US9128101B2 · kind B2 · utility

Assignee

• Caris Life Sciences Switzerland Holdings GMBH · CH

Inventors

• David D. Halbert · Colleyville, US
• Christine Kuslich · Gilbert, US
• George Poste · Cave Creek, US
• Michael Klass · Libertyville, US
• David Spetzler · Scottsdale, US
• Traci Pawlowski · Laguna Niguel, US
• Andrea Tasinato · Gimel, CH
• Daniel Holterman · Phoenix, US

Key dates

• Filing date: Mar 1, 2011
• Grant date: Sep 8, 2015
• Expiry date: Mar 1, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/60
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.